Press Room

Hovione speakers at the QRM Summit

Start
Thursday, May 11, 2017 - 08:30
End
Thursday, May 11, 2017 - 15:30
Location: Lisbon, Portugal

HOVIONE PRESENTATIONS

Guy Villax, CEO
8:30 - 9:15 am

Guy Villax will be the keynote speaker at the second day of the Quality Risk Management Summit. Under the Supply Chain Integrity block, Guy's talk will address the topic Do patients want capsules full of compliance, or full of quality? Why Quality culture wins every time.

 

Joerg Gampfer, Senior Director Quality
11:30 - 12:00

The whole is more than the sum of the pieces - building strategy on Knowledge and Risk Management

 

Luisa Paulo, GMP Compliance Director and ICH Q12 Team Member
14:00 - 15:00

QRM Enabled Post-Approval Changes & Lifecycle Management within ICHQ12

 

You might be also interested in:

 

Quality Culture Wins Over Compliance

Pharma's Almanac, June 2016

Why Dr. Hamburg Needs Her Dean’s List

Guy Villax Letter, June 2014

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025